Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL590222 | 0.77 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL592236 | 0.77 | GRM2 (0.33) | KCNH2 | |
| SCHEMBL590245 | 0.77 | GRM2 (0.33) | KCNH2 | |
| SCHEMBL590299 | 0.77 | KCNH2 (0.32) | KCNH2 | |
| SCHEMBL590281 | 0.77 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL592742 | 0.77 | KCNH2 (0.32) | KCNH2 | |
| SCHEMBL591594 | 0.77 | KCNH2 (0.32) | KCNH2 | |
| SCHEMBL589831 | 0.77 | KCNH2 (0.32) | KCNH2 | |
| SCHEMBL590884 | 0.77 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL591642 | 0.77 | KCNH2 (0.34) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999115-B2 | Spiro antibiotic derivatives | ACTELION PHARMACEUTICAL LTD. (SE) | 2011-08-16 | — | — | US | claimed |
| EP-2066678-B1 | SPIRO ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-02-10 | — | — | EP | claimed |
| US-20090270375-A1 | SPIRO ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-29 | — | — | US | claimed |
| EP-2066678-A1 | SPIRO ANTIBIOTIC DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-10 | — | — | EP | claimed |
| WO-2008026172-A1 | SPIRO ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-06 | — | — | WO | claimed |
| US-7999115-B2 | Spiro antibiotic derivatives | ACTELION PHARMACEUTICAL LTD. (SE) | 2011-08-16 | — | — | US | disclosed |
| EP-2066678-B1 | SPIRO ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-02-10 | — | — | EP | disclosed |
| US-20090270375-A1 | SPIRO ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-29 | — | — | US | disclosed |
| EP-2066678-A1 | SPIRO ANTIBIOTIC DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008026172-A1 | SPIRO ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270375-A1 | SPIRO ANTIBIOTIC DERIVATIVES | NR0B1, NRDC, NR4A1 | KCNH2 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.